AfMen Vaccine

AfMen Vaccine is a preclinical viral vector vaccine candidate being developed by VaxThera, a Colombian biotechnology company. The vaccine is intended to target 'AfMen,' which is interpreted as meningococcal disease (meningitis) caused by *Neisseria meningitidis*, particularly strains prevalent in the African meningitis belt. Although the project is listed within VaxThera's veterinary pipeline in some company documentation, the target pathogen is primarily a human health concern. The vaccine utilizes a viral vector platform, distinguishing it from existing conjugate vaccines like MenAfriVac. It aims to provide an affordable and effective immunization option for regions affected by meningococcal outbreaks and is currently in the preclinical stage of research and development.

Other names

VaxThera AfMen vaccineMenAfriVac-VaxThera-viral vector-AfMen